Glancy Binkow & Goldberg Encourages Investors to Inquire About a Lead Plaintiff Position in the Class Action Lawsuit Against

Glancy Binkow & Goldberg Encourages Investors to Inquire About a Lead
Plaintiff Position in the Class Action Lawsuit Against Affymax, Inc. -- AFFY

LOS ANGELES, April 28, 2013 (GLOBE NEWSWIRE) -- Glancy Binkow & Goldberg LLP,
representing investors of Affymax, Inc. ("Affymax" or the "Company")
(Nasdaq:AFFY), has filed a class action lawsuit in the United States District
Court for the Northern District of California on behalf of a class (the
"Class") comprising all purchasers of Affymax securities between December 8,
2011 and February 22, 2013, inclusive (the "Class Period"). Investors who have
losses of $100,000 or more are encouraged to contact the firm for information
concerning a lead plaintiff position in the class action suit and have until
April 29, 2013 to file a motion with the Court to be appointed as lead
plaintiff.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW &
GOLDBERG LLP. PLEASE CONTACT US BY PHONE TO DISCUSS THIS ACTION OR TO OBTAIN A
COPY OF THE COMPLAINT AT (310) 201-9150, TOLL-FREE AT (888) 773-9224, OR BY
EMAIL AT SHAREHOLDERS@GLANCYLAW.COM.

On February 23, 2013 Affymax and Japan-based Takeda Pharmaceutical Company
Limited (Takeda) issued a joint announcement of a nationwide voluntary recall
of OMONTYS (peginesatide) Injection. OMONTYS Injection is a treatment for
anemia due to chronic kidney disease in adult patients on dialysis. Affymax
has a strategic alliance agreement with Takeda to develop and commercialize
OMONTYS. According to the Company, the recall is related to "new postmarketing
reports regarding serious hypersensitivity reactions, including anaphylaxis,
which can be life-threatening or fatal." The Complaint alleges that defendants
failed to disclose that 0.02% of patients who were administered OMONTYS
experienced fatal anaphylaxis reactions.

If you purchased Affymax shares during the Class Period, you have until April
29, 2013 to move the Court to serve as lead plaintiff; however, you must meet
certain legal requirements. If you wish to learn more about this action or
have any questions concerning this Notice or your rights or interests with
respect to these matters, please contact Michael Goldberg, Esquire, of Glancy
Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067, by telephone at (310) 201-9150 or Toll Free at (888)
773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

CONTACT: Glancy Binkow & Goldberg LLP, Los Angeles, CA
         Michael Goldberg
         (310) 201-9150 or (888) 773-9224
         shareholders@glancylaw.com
         www.glancylaw.com

Company Logo